A group of experts will be discussing the risks associated with the Type 2 diabetes drug, Invokana, at an upcoming American Association of Clinical Endocrinologists conference. The conference is set for October 24thand 25th in Dallas. The conference was called in response to the more than 450 adverse event reports regarding Invokana and other SLGT-2 inhibitor drugs such as Farxiga, Jardiance Xigduo XR, Invokamet and Glyxambi. A number of these adverse event reports are for diabetic ketoacidosis, a potentially deadly disease.
When Invokana Use Leads to Diabetic Ketoacidosis
Diabetic ketoacidosis is usually only seen in patients with Type 1 diabetes when it develops from an injury, serious illness, infection, surgery, or from missing a scheduled dosage of insulin. When the body is unable to use sugar as fuel due to the lack of insulin in the body, it uses fat instead. As the fat in the body begins to break down, ketones—a waste product—build up in the blood and urine. It is theorized that diabetic ketoacidosis can occur in those taking Invokana due to the way SGLT-2 inhibitors prevent the kidneys from reabsorbing glucose back into the bloodstream.
Excess blood glucose is eliminated through the kidneys in the patient’s urine. Diabetic ketoacidosis can cause nausea, vomiting, fatigue, sleepiness, confusion, abdominal pain, stiff muscles, fruity-smelling breath, frequent urination, dry mouth and skin and rapid breathing. Vomiting in a person taking Invokana which lasts more than two hours, requires immediate medical attention. Potential complications from diabetic ketoacidosis include fluid buildup in the brain, bowel tissue death, kidney disease, kidney failure and heart attack. Diabetic ketoacidosis can also lead to coma and death.
Results of the AACE Conference May Help Those Injured by Invokana
Experts from around the world will take part in the AACE conference to discuss the risks associated with Invokana and other SGLT-2 inhibitor drugs. The AACE is comprised of more than 6,000 medical professionals who routinely treat patients with diabetes, both Type 1 and Type 2. Participating AACE experts will examine data taken from the FDA adverse event reports as well as other studies associated with SGLT-2 inhibitor drugs, then will make recommendations regarding the risk-benefit calculations associated with Invokana. AACE president, Dr. George Grunberger notes the responsibility of the AACE is to its members and to diabetic patients. Grunberger further stated the panel will conduct a “complete, objective and balanced evaluation of the data…” before they make their recommendations.
Kidney Disease and Heart Attack Also Associated with Invokana
In addition to diabetic ketoacidosis, Invokana has been linked to kidney failure and heart attack/heart failure. Prior to the 10-5 vote by the FDA to approve Invokana, concern regarding the potential risk of cardiovascular events was voiced, however the majority of the panel determined there were more benefits associated with the drug than risks. Renal failure has also been linked to Invokana.
Diabetic patients are already prone to developing kidney issues; when a drug which may cause kidney disease or kidney failure is taken, those risks increase exponentially. Further, diabetic ketoacidosis, when not promptly treated, can lead to kidney failure. Patients taking Invokana must be aware of health symptoms such as a metallic taste in the mouth, pain between the rib and hip area, decreased appetite, changes in urination, unusual fatigue, lessened sensation in the extremities, vomiting and nausea, swollen ankles, legs or feet and difficult breathing.
Those who are considering filing an Invokana lawsuit due to injury suffered from the drug will be anxiously awaiting the results of the AACE conference. Having a knowledgeable Invokana attorney by your side during this difficult time can ensure your rights and your future are properly protected.